HOME >> BIOLOGY >> NEWS
Introgens gene drug demonstrates tumor growth control

or that the proposed treatments will prove to be safe and/or effective. The actual results may differ from those described in this press release due to risks and uncertainties that exist in Introgens operations and business environment, including, but without limitation, Introgens stage of product development and the limited experience in the development of gene-based drugs in general, its dependence upon proprietary technology and current competition, history of operating losses and accumulated deficits, Introgens reliance on collaborative relationships, and uncertainties related to clinical trials, safety, efficacy, the ability to obtain the appropriate regulatory approvals, patent protection and market acceptance, as well as other risks detailed from time to time in Introgens filings with the Securities and Exchange Commission, including its prospectus dated October 12, 2000, filed with the Securities and Exchange Commission and the 10-K filed with the Securities and Exchange Commission on September 19, 2001. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising from the date hereof.


'"/>

Contact: Channing Burke
c.burke@introgen.com
512-708-9310
Porter Novelli
25-Oct-2001


Page: 1 2 3 4

Related biology news :

1. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
2. Study demonstrates altered angiogenic proteins in preeclampsia patients
3. New study demonstrates bone protein can reverse kidney failure
4. Study demonstrates that low dose tamoxifen may be effective in treating breast cancer
5. Animal study demonstrates carbon monoxide may help heart patients
6. Binary enzyme created by TSRI scientists demonstrates Darwinian evolution at its simplest
7. New UGA study demonstrates bacterial pathogens use hydrogen as energy source in animals
8. Inhibitor of novel cancer target, LPAAT-beta, demonstrates selective anti-cancer effects
9. Norwegian study demonstrates targeted coxibs may prevent oral cancer
10. New physical activity opinion survey demonstrates perceptions do not meet reality
11. Testosterone gel (AndroGel) study demonstrates safety and efficacy up to 42 months

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Introgens gene drug demonstrates tumor growth control

(Date:12/22/2014)... 2014  The 2014 Holiday Season may be the brightest ... reports that the long anticipated floodgates for consumer biometrics ... for smart phones, tablets, and wearable mobile devices that ... billion users with nearly 4.8 billion biometric devices by ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized mobile ... Internet of Things era, today announced the close of ... was led by Metamorphic Ventures with participation from ENIAC ... and others.  LaunchKey has raised $4 million to date, ...
(Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
Cached News: